CenterBook Partners’s Agios Pharmaceuticals AGIO Stock Holding History

CenterBook Partners’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-21,885	Closed	-$812K	–	861
2026 Q2	$812K	Buy	21,885 +4,440	+25%	+$135K	0.04%	403
2026 Q1	$590K	Buy	+17,445	New	+$495K	0.03%	453
2025 Q3	–	Sell	-243,063	Closed	-$8.08M	–	550
2025 Q2	$8.08M	Buy	243,063 +134,554	+124%	+$4.08M	0.45%	48
2025 Q1	$3.18M	Sell	108,509 -197,090	-64%	-$6.54M	0.2%	134
2024 Q4	$10M	Buy	305,599 +151,511	+98%	+$7.12M	0.6%	35
2024 Q3	$6.85M	Sell	154,088 -95,223	-38%	-$4.32M	0.42%	72
2024 Q2	$10.8M	Buy	+249,311	New	+$9M	0.67%	24

Other funds holding AGIO

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

CenterBook Partners's AGIO Position: Q3 2026 in Review

CenterBook Partners sold out of Agios Pharmaceuticals (AGIO) in Q3 2026, closing a stake of 21,885 shares — an estimated $812K sold.

CenterBook Partners first reported a position in AGIO in Q2 2024 and held it in 7 quarters. The position peaked at $10.8M in Q2 2024. 111 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

CenterBook Partners reported no remaining Agios Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
CenterBook Partners sold 21,885 Agios Pharmaceuticals shares in Q3 2026, an estimated $812K.
CenterBook Partners first reported a position in Agios Pharmaceuticals in Q2 2024 and held it in 7 quarters.
CenterBook Partners's Agios Pharmaceuticals position peaked at $10.8M in Q2 2024.
111 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.